Cardiff Oncology (NASDAQ:CRDF) Upgraded at Wall Street Zen

Cardiff Oncology (NASDAQ:CRDF) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

CRDF has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Cardiff Oncology in a research note on Wednesday, January 28th. Noble Financial initiated coverage on Cardiff Oncology in a research report on Monday, January 5th. They set an “outperform” rating and a $12.00 price target for the company. Piper Sandler decreased their price target on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.10.

Cardiff Oncology Price Performance

Shares of CRDF stock opened at $1.89 on Wednesday. The stock’s 50-day moving average is $2.28 and its 200 day moving average is $2.24. Cardiff Oncology has a 1-year low of $1.48 and a 1-year high of $4.56. The company has a market cap of $129.20 million, a P/E ratio of -2.74 and a beta of 1.32.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Tuesday, February 24th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.07. Cardiff Oncology had a negative net margin of 7,733.22% and a negative return on equity of 82.01%. The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.13 million. On average, analysts anticipate that Cardiff Oncology will post -0.99 EPS for the current year.

Institutional Trading of Cardiff Oncology

A number of institutional investors have recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in shares of Cardiff Oncology during the 4th quarter valued at about $108,000. XTX Topco Ltd raised its stake in Cardiff Oncology by 40.5% during the fourth quarter. XTX Topco Ltd now owns 219,357 shares of the company’s stock worth $616,000 after purchasing an additional 63,196 shares during the period. Millennium Management LLC boosted its holdings in Cardiff Oncology by 441.5% in the 4th quarter. Millennium Management LLC now owns 194,420 shares of the company’s stock valued at $546,000 after purchasing an additional 158,519 shares during the last quarter. Laurion Capital Management LP boosted its holdings in Cardiff Oncology by 7.3% in the 4th quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock valued at $7,437,000 after purchasing an additional 180,866 shares during the last quarter. Finally, Tamar Securities LLC purchased a new stake in shares of Cardiff Oncology in the 4th quarter valued at approximately $32,000. 16.29% of the stock is owned by institutional investors and hedge funds.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.